KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Inventory (2016 - 2025)

AbbVie (ABBV) has disclosed Inventory for 14 consecutive years, with $5.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 18.42% to $5.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 billion, a 18.42% increase, with the full-year FY2025 number at $5.0 billion, up 18.42% from a year prior.
  • Inventory was $5.0 billion for Q4 2025 at AbbVie, roughly flat from $4.9 billion in the prior quarter.
  • In the past five years, Inventory ranged from a high of $5.0 billion in Q2 2025 to a low of $3.1 billion in Q3 2021.
  • A 5-year average of $3.9 billion and a median of $4.0 billion in 2023 define the central range for Inventory.
  • Biggest YoY gain for Inventory was 77.44% in 2021; the steepest drop was 16.58% in 2021.
  • AbbVie's Inventory stood at $3.1 billion in 2021, then increased by 14.42% to $3.6 billion in 2022, then rose by 14.53% to $4.1 billion in 2023, then increased by 2.0% to $4.2 billion in 2024, then increased by 18.42% to $5.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Inventory are $5.0 billion (Q4 2025), $4.9 billion (Q3 2025), and $5.0 billion (Q2 2025).